Pre-earnings brief
Reports
Tue, May 5, 2026
Est. EPS
$-0.54
Est. revenue
$0M
Implied move
±10.3%
EPS beat rate
13%
Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for rare genetic diseases. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for patients.
Last quarter
In the last quarter, Cogent reported an EPS of $-0.64, missing estimates by 17%. The stock reacted with a slight decline of 0.19% the following day.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-13.59%
Avg 1-day reaction
+3.32%
Analysts expect Cogent to report a loss of $-0.54 per share this quarter, continuing a trend of losses. Investors will be looking for any signs of progress in drug development or partnerships.
Bull case
If Cogent can show promising results in its drug trials or announce new partnerships, it could lead to a positive reassessment of its future earnings potential.
Bear case
Conversely, if the company fails to provide any updates on its pipeline or continues to miss EPS estimates, it could lead to further declines in stock price.
Key metrics to watch
EPS
$-0.54Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.
Revenue
$0MAlthough no revenue is expected this quarter, any updates on future revenue streams or partnerships could be significant.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.54?
A smaller loss than expected could indicate improved operational efficiency or progress in drug development.
Q2
What updates can management provide regarding its drug pipeline?
Investors are keen to hear about any advancements or setbacks in drug trials, which could significantly impact future revenue potential.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for positive news from ongoing drug trials, which could lead to a more favorable outlook than currently priced in.
Supporting evidence
The options market is pricing a 10.34% move, indicating expectations for significant volatility.
Historically, the stock has reacted positively even after EPS misses, suggesting resilience.
The lack of recent insider activity could imply that insiders are not overly concerned about the upcoming results.
Key risk
If the company provides strong updates on its drug pipeline, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is weighing the potential for recovery against ongoing losses and the company's ability to deliver on its drug development promises.
Bull confirmed if
A reported EPS loss of less than $-0.54, coupled with positive updates on drug trials, would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-0.54 without any positive news on the pipeline would confirm the bear case.
What the market is pricing for the move.
Implied Move
±10.34%
Historical Avg
±3.4%
The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±10.3% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.
30d HV
51.9%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.2% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
103.29%
of float
Insider
0.29%
of float
Holders
362
institutions
Top Holders· as of Dec 2025
FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cogent beats expectations and raises guidance, history suggests the stock could rise by an average of 2.45% on the following day.
In line / cautious
If results are in line with expectations but management is cautious, the stock may see a muted reaction, reflecting uncertainty.
Miss
If Cogent misses estimates, history suggests the stock could decline by an average of 3.44%, reflecting disappointment among investors.
The lines on the call that would change the story.
Blackrock Inc.
12,974,591 sh · $477.6M
7.99%
25.1%
Vanguard Group Inc
11,514,326 sh · $423.8M
7.09%
48.4%
Deerfield Management Company, L.P
9,043,903 sh · $332.9M
5.57%
-0.1%
Fairmount Funds Management LLC
9,003,418 sh · $331.4M
5.55%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.